Secukinumab: a human IgG1κ monoclonal antibody that binds to IL-17A ASAS40: a composite measure including patient global, pain, function, and inflammation In patients with nr-AxSpA, secukinumab improved ASAS40 through week 52, compared to placebo Dr. Deodhar #ACR19 @RheumNow https://t.co/yLwt47w2wr